Understanding Modafinil Research Findings On A Wakefulness-Promoting Medication

The provided source material is insufficient to produce a 2000-word article about free modafinil samples. Below is a factual summary based on available data.

Research Overview

Modafinil is a medication approved for narcolepsy and shift work sleep disorder. Clinical research indicates that it has both dopaminergic and glutamatergic activity that may be useful for the treatment of cocaine dependence. Studies have shown that modafinil has reduced cocaine subjective effects and cocaine self-administration in human laboratory trials and has reduced cocaine use in cocaine dependent patients in some clinical trials.

Clinical Trial Evidence

A clinical trial published in Front Psychiatry investigated the combination of modafinil and d-amphetamine for the treatment of cocaine dependence. This was an 8-week, double-blind, placebo-controlled clinical trial involving 94 cocaine dependent subjects. Participants received 300 mg of modafinil or identical placebo daily along with weekly individual therapy. The primary outcome measure was cocaine use measured by self-report, and confirmed by twice weekly urine benzoylecgonine tests (UBT). Additional outcome measures included cocaine craving measured by the Brief Substance Craving Scale and global improvement measured by the Clinical Global Impression Scale (CGI).

This trial was the second in which modafinil was superior to placebo in the predefined primary outcome in the complete sample. In the first controlled trial of modafinil, Dackis and colleagues found that modafinil-treated subjects submitted more negative UBT compared to placebo treated subjects. In other trials, post-hoc analyses support the efficacy of modafinil for subgroups of cocaine dependent patients. For instance, in a multicenter trial of modafinil for cocaine dependence, Anderson and colleagues showed that cocaine dependent subjects without comorbid alcohol dependence had significantly more cocaine non-use days if they were treated with modafinil compared to placebo. In another trial, Dackis and colleagues found that men treated with modafinil submitted significantly fewer cocaine positive UBT.

Pharmacological Properties

Research has shown that modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. Studies have demonstrated that modafinil shifts human locus coeruleus to low tonic, high-phasic activity during functional MRI.

Two doses of modafinil (200 mg and 400 mg) have been evaluated in research settings. Neither the plasma modafinil concentrations nor the dopamine transporter blockade or dopamine changes differed between the two doses, which may reflect the relatively small sample of the study. The lack of a dose effect is also confounded by the large participant variability in modafinil's plasma concentrations, particularly for one participant in the 400-mg dose group, which predicted the level of dopamine transporter occupancy.

Research Methodology

In clinical studies examining modafinil's effects, participants were blinded to whether they would receive placebo or modafinil or the dose received. Measures of modafinil concentration in plasma were obtained at 2 hours after modafinil administration (corresponding to the time of scan initiation) and analyzed using high-performance liquid chromatography with spectrophotometric detection.

Radiotracer synthesis and positron emission tomographic (PET) imaging studies have been conducted to examine modafinil's effects on the brain. These studies used [11C]Cocaine synthesized according to established methods, with radiochemical purity greater than 98%. Dynamic PET imaging was carried out on high-resolution, whole-body PET scanners in three-dimension acquisition mode.

Additional Research References

Additional studies referenced in the source material include research on: - The Mini-International Neuropsychiatric Interview (M.I.N.I.), a structured diagnostic psychiatric interview for DSM-IV and ICD-10 - The Alcohol Timeline Followback Users' Manual for assessing alcohol consumption - Development of scales for measuring drug craving - Effects of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain

Conclusion

The provided source material contains scientific research on modafinil's pharmacological properties and clinical applications, particularly regarding its potential use in treating cocaine dependence. However, there is no information available about free sample programs, promotional offers, or access to modafinil samples for consumers. The research focuses on clinical trials and scientific studies rather than consumer access or sample distribution programs. No information was found about eligibility requirements for obtaining samples, how to access samples, or any brand-sponsored sample programs for modafinil.

Sources

1. PMC2696807
2. PMC4582003